Kacsir István, Sipos Adrienn, Bényei Attila, Janka Eszter, Buglyó Péter, Somsák László, Bai Péter, Bokor Éva
Department of Organic Chemistry, University of Debrecen, P.O. Box 400, H-4002 Debrecen, Hungary.
Doctoral School of Chemistry, University of Debrecen, P.O. Box 400, H-4002 Debrecen, Hungary.
Int J Mol Sci. 2022 Jan 12;23(2):813. doi: 10.3390/ijms23020813.
Platinum complexes are used in chemotherapy, primarily as antineoplastic agents. In this study, we assessed the cytotoxic and cytostatic properties of a set of osmium(II), ruthenium(II), iridium(III) and rhodium(III) half-sandwich-type complexes with bidentate monosaccharide ligands. We identified 5 compounds with moderate to negligible acute cytotoxicity but with potent long-term cytostatic activity. These structure-activity relationship studies revealed that: (1) osmium(II) -cymene complexes were active in all models, while rhodium(III) and iridium(III) Cp* complexes proved largely inactive; (2) the biological effect was influenced by the nature of the central azole ring of the ligands-1,2,3-triazole was the most effective, followed by 1,3,4-oxadiazole, while the isomeric 1,2,4-oxadiazole abolished the cytostatic activity; (3) we found a correlation between the hydrophobic character of the complexes and their cytostatic activity: compounds with -benzoyl protective groups on the carbohydrate moiety were active, compared to -deprotected ones. The best compound, an osmium(II) complex, had an IC value of 0.70 µM. Furthermore, the steepness of the inhibitory curve of the active complexes suggested cooperative binding; cooperative molecules were better inhibitors than non-cooperative ones. The cytostatic activity of the active complexes was abolished by a lipid-soluble antioxidant, vitamin E, suggesting that oxidative stress plays a major role in the biological activity of the complexes. The complexes were active on ovarian cancer, pancreatic adenocarcinoma, osteosarcoma and Hodgkin's lymphoma cells, but were inactive on primary, non-transformed human fibroblasts, indicating their applicability as potential anticancer agents.
铂配合物主要作为抗肿瘤药物用于化疗。在本研究中,我们评估了一组含有双齿单糖配体的锇(II)、钌(II)、铱(III)和铑(III)半夹心型配合物的细胞毒性和细胞生长抑制特性。我们鉴定出5种化合物,它们具有中度至可忽略不计的急性细胞毒性,但具有强大的长期细胞生长抑制活性。这些构效关系研究表明:(1)锇(II)-对异丙基苯配合物在所有模型中均有活性,而铑(III)和铱(III)茂金属配合物在很大程度上无活性;(2)生物效应受配体中心唑环性质的影响——1,2,3-三唑最有效,其次是1,3,4-恶二唑,而异构体1,2,4-恶二唑则消除了细胞生长抑制活性;(3)我们发现配合物的疏水特性与其细胞生长抑制活性之间存在相关性:与去保护的化合物相比,碳水化合物部分带有苯甲酰保护基的化合物具有活性。最佳化合物,一种锇(II)配合物,IC值为0.70μM。此外,活性配合物抑制曲线的陡峭程度表明存在协同结合;协同分子比非协同分子是更好的抑制剂。活性配合物的细胞生长抑制活性被脂溶性抗氧化剂维生素E消除,这表明氧化应激在配合物的生物活性中起主要作用。这些配合物对卵巢癌、胰腺腺癌、骨肉瘤和霍奇金淋巴瘤细胞有活性,但对原代未转化的人成纤维细胞无活性,表明它们作为潜在抗癌药物的适用性。